4 years ago

Rinri Therapeutics Secures £10 Million to Develop Stem Cell Therapy for Hearing Loss

  • Rinri Therapeutics, a UK-based biotechnology company developing a novel stem cell therapy to restore hearing, raised £10 million in funding

  • Backers included existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund

  • The proceeds will support the development of the company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).

      • ProblemHealthcare

      "Millions of people suffer from sensorineural hearing loss (SNHL), which is irreversible damage to the inner ear's sensory cells. Current treatments are limited, leaving patients with no option for restoring their hearing."

      Solution

      "Rinri Therapeutics has developed a novel stem cell therapy that aims to repair the damaged inner ear, potentially restoring hearing for SNHL patients. This groundbreaking therapy harnesses the power of stem cells to regenerate the sensory cells responsible for hearing."

      Covered on